Wegovy vs Mounjaro for Weight Loss: Why Comparing Matters
Comparing Wegovy and Mounjaro matters if you track weight loss and expect measurable results. Clinical trials report average body‑weight loss of about 20% for Mounjaro and about 14% for Wegovy in comparable trials (Medical News Today).
A head‑to‑head trial found 32% of participants on Mounjaro lost at least 25% of their body weight. By comparison, 16% of Wegovy users reached that threshold (BBC). Those outcome gaps change expectations and influence how you interpret day‑to‑day progress.
Cost differences can also affect long‑term adherence. As of September 2026, list prices are approximately $1,349 per month for Wegovy and around $1,060–$1,070 per month for Mounjaro/Zepbound; actual out‑of‑pocket costs vary by insurance, pharmacy, and manufacturer savings programs. See price listings on GoodRx for current estimates (Wegovy on GoodRx, Mounjaro on GoodRx). Prices change over time and may differ from these examples.
Pepio helps you record dose dates, weight, symptoms, and shot history. Pepio lets you log doses, symptoms, injection sites, and weight, then export clean timelines for clinician review.
Pepio's approach focuses on tracking and organization, not medical advice. Pepio is for organization and self‑tracking only; always follow the instructions from your clinician, prescriber, pharmacist, or medication label for treatment decisions. Learn more about Pepio's approach to tracking GLP‑1 and peptide routines.
Key Criteria for Comparing Weight‑Loss Options
Use a simple 5‑Factor Weight‑Loss Evaluation Framework to compare GLP‑1 options. These five practical criteria help you weigh trial results, daily routines, and real costs. Clinical trials often report average weight loss and long follow‑up periods, so use trial numbers as a starting point—not a guarantee (Systematic Review of GLP‑1 Receptor Agonists for Obesity).
- Clinical effectiveness (average % weight loss)
-
Trial averages show typical outcomes to compare therapies.
-
Dosing frequency and flexibility
-
How often you dose and how titration works affects adherence.
-
Common side‑effects and their timeline
-
Timing and severity of side effects shape tolerability.
-
Out‑of‑pocket cost and insurance considerations
-
Price, coverage, and access vary by therapy and plan.
-
Availability of tracking tools to monitor progress
- Check whether you can log doses, symptoms, and weight; tools like Pepio keep routine details in one place (track, reminders, dose history).
Clinical trials report average weight loss around 10–15% over multi‑month follow‑ups (Systematic Review of GLP‑1 Receptor Agonists for Obesity). Head‑to‑head and phase‑3 datasets show different averages by drug; some reports place one option in the mid‑teens and others higher in the high‑teens to low‑twenties (Medical News Today, BBC). Study durations commonly range from 40 to 120 weeks, so look at longer trials for sustained effects. Remember trial averages do not guarantee individual results and real‑world outcomes may differ.
Most GLP‑1 weight‑loss therapies use once‑weekly dosing, but titration steps and maximum doses differ between drugs (FDA label for Mounjaro, Medical News Today). Titration schedules can affect short‑term tolerability and how closely you need to track doses. That makes reliable reminders and a clear dose history useful for adherence. Pepio's approach focuses on the operational layer of routines, helping you record dose dates, track titration steps, and keep symptoms and weight changes together for easier review.
Pepio Tracker: Organize Shots, Symptoms, and Progress
Pepio organizes dose dates, doses, and injection sites in one place so your shot history stays complete. That record makes it easier to interpret differences between medications. Clinical studies show GLP‑1 therapies can produce different average weight‑loss results (Systematic Review of GLP‑1 Receptor Agonists for Obesity).
Linking symptom and food‑noise notes to dose history helps you spot patterns over time. Some studies suggest greater engagement with digital self‑monitoring is associated with larger short‑term weight loss, so frequent, consistent tracking tends to matter.
Daily self‑monitoring improves sustained weight loss compared with weekly logging, so frequent notes matter (Healthline – Tracking Weight Loss on GLP‑1s). Pairing weight charts with reminders supports consistency and retention. Digital programs that include reminders and exportable reports retain more users and show clearer ROI for clinicians and payers (Diabetes & Metabolism Journal – Digital Engagement Study).
Key tracking elements to keep together:
- All‑in‑one injection log (date, dose, site)
- Symptom and food‑noise tracking for pattern detection
- Weight‑loss progress charts linked to dose history
- Automatic reminders to maintain weekly consistency
- Exportable reports to bring to clinician visits
Exportable reports make follow‑up visits smoother by summarizing dose history, symptoms, and weight trends. Pepio's approach ties those summaries to reminders so you keep consistent notes between appointments. Learn more about Pepio's approach to organizing GLP‑1 tracking and preparing notes for clinician visits.
Pepio features at a glance:
- Free iOS app (base) with optional Pepio Plus upgrade
- 24 free, no‑sign‑up web tools that run in your browser
- Privacy‑first: no personal data stored on Pepio servers; calculations and tools run client‑side
- Exportable CSV / PDF logs for clinician sharing
- Push reminders and injection‑site rotation memory
- Custom medication support (add your own meds)
- AI visit‑prep notes and side‑effect assistant tools
Try Pepio to keep your shots, symptoms, and progress in one place — download the free iOS app or use the web tools and track your next shot in Pepio. Pepio is for organization and self‑tracking only and does not provide medical advice. Always follow the instructions from your clinician, prescriber, pharmacist, or medication label.
Wegovy vs Mounjaro: Dosing, Effectiveness, and Side Effects
In head‑to‑head data, Mounjaro produced larger average weight loss than Wegovy over 72 weeks. Mounjaro averaged about 20% weight loss versus roughly 14% for Wegovy in the same trial (BBC). That difference matters if your goal is maximal percentage loss, but individual response varies widely.
Dosing and titration also differ. Wegovy typically escalates weekly from low doses to a 2.4 mg weekly target to reduce gastrointestinal intolerance. Tirzepatide products (Mounjaro for type‑2 diabetes and Zepbound for weight management) start at 2.5 mg weekly and escalate up to a maximum of 15 mg weekly; see the Mounjaro FDA label and the Zepbound FDA label for each product's approved titration schedule (Medical News Today; Mounjaro FDA label; Zepbound FDA label). These schedules affect how often you record dose changes and titration dates.
Side‑effect patterns overlap but show nuance. Both drugs commonly cause gastrointestinal side effects such as nausea, vomiting, diarrhea, and constipation. Gallbladder events and hypersensitivity reactions have been reported with GLP‑1 and GLP‑1/GIP therapies, but reported rates and specific event types vary by study and population; summaries and trial reports differ on which events are more frequent for each product (Medical News Today). Use consistent logging to track timing and severity after each dose.
Cost and access affect adherence. Out‑of‑pocket prices and insurance coverage vary between the two drugs and by pharmacy. Those differences can influence whether people stick with treatment or switch products, so track claims, prior‑authorization outcomes, and monthly costs (GoodRx).
What to log to interpret personal results: dose amount and titration dates, injection dates and missed doses, weight and percentage change, symptom timing and severity, and any insurance or cost changes. Tools like Pepio help you keep these fields together so you can spot trends. Users who log consistently can bring clearer notes to clinicians and better understand whether changes align with dose adjustments.
Pepio is for organization and self‑tracking only. Follow your clinician’s instructions, and contact a health professional for medical concerns. Learn more about Pepio’s approach to tracking GLP‑1 routines and keeping dose history, symptoms, and weight progress in one place.
Keeping a short, consistent log after each shot makes your treatment easier to understand and discuss. Daily quick checks help you spot patterns sooner and prepare clearer notes for appointments.
- Date and exact dose you were instructed to take
- Injection site and rotation note (e.g., 'left abdomen, week 3')
- Timing and description of symptoms (nausea, appetite changes, food-noise)
- Daily weight and percentage change over time
- Missed doses or schedule shifts and reason (travel, illness)
- Insurance or cost changes that might affect continuity
Do a brief daily check for weight and symptoms, and add fuller notes weekly. A digital engagement study shows frequent self-monitoring boosts consistency and engagement (Diabetes & Metabolism Journal). Tracking weight regularly also clarifies short‑term changes and trends (Healthline).
Pepio helps you keep these fields in one place so you see trends without searching through screenshots. Users using Pepio report clearer, exportable records for clinician visits. Pepio's approach to routine tracking enables simpler preparation for follow-ups. Learn more about Pepio's approach to GLP-1 tracking to keep your dose history, symptoms, and weight progress organized.
Pepio is for organization and self-tracking only. Always follow instructions from your clinician, prescriber, pharmacist, or medication label.
Head‑to‑head trial reports suggest differences, but results vary by study and population. Some analyses found Mounjaro showed slightly larger average weight loss than Wegovy in a direct comparison (BBC). Summaries and reviews note both drugs can produce meaningful weight loss, with individual responses differing (Medical News Today).
No. Don’t change medications solely on published averages or short‑term results. Discuss your goals, side effects, and medical history with your clinician before switching. Trials use controlled conditions that may not match your routine or priorities (Medical News Today).
- Date, time, and dose you were instructed to take
- Injection site and any rotation notes
- Symptoms within 24–72 hours and appetite or food noise changes
- Weight or percentage change at regular intervals Keeping these fields makes trends easier to review with your clinician.
Digital trackers can improve organization and visit prep when used thoughtfully. Studies show well‑designed digital engagement can help users keep clearer medication and symptom records (Diabetes & Metabolism Journal). Solutions like Pepio help you record doses, symptoms, and progress without offering medical advice.
Use your notes to guide conversations with your clinician. Learn more about Pepio’s approach to tracking and how it helps keep your dose history, symptoms, and weight progress in one place. Pepio is for organization and self‑tracking only. Pepio does not provide medical advice, diagnosis, treatment, or dosing recommendations. Always follow instructions from your clinician, prescriber, pharmacist, or medication label.
Mounjaro has tended to show higher average weight loss than some alternatives in head‑to‑head comparisons, but individual results vary widely (Medical News Today). Tracking what you actually do each week makes those differences clear. Record dose dates, symptoms, appetite changes, and weight so you can spot trends and link them to dose changes or timing. Research on digital engagement suggests organized self‑tracking improves follow‑up conversations and helps clinicians act on clearer notes (Diabetes & Metabolism Journal). Pepio helps you keep dose history, symptom logs, and weight progress in one place so you can review patterns over weeks. People using Pepio report easier note‑sharing and cleaner records for clinic visits. Pepio’s practical approach focuses on routine organization, not medical advice.
Regardless of which medication you use, consider Pepio: the free web tools and free iOS app built for GLP‑1 and peptide tracking. Pepio offers privacy‑first, browser‑based calculators and a free app with exportable, clinician‑ready reports to help you keep dose history, symptoms, injection sites, and weight progress organized for visits.
Pepio is for organization and self‑tracking only. Pepio does not provide medical advice, diagnosis, treatment, or dosing recommendations. Always follow your clinician, prescriber, pharmacist, or medication label. Learn more about Pepio’s approach to organizing GLP‑1 routines to prepare better notes for your next visit.